Breast cancer remains one of the greatest public health concerns worldwide. Despite advances in early diagnosis and targeted therapies, it continues to be the most common cause of cancer-related death among women. However, new research suggests that a well-known medication, traditionally used to lower cholesterol, may play an unexpected role in breast cancer prevention.
A recent study published in Scientific Reports provides compelling evidence that atorvastatin may reverse early molecular alterations that predispose to breast cancer. In other words, this drug, widely used to treat high cholesterol, could help “reprogram” breast cells toward a healthier state, less prone to tumor transformation.
A New Approach to Understanding Cancer Prevention
Most breast cancer research has focused on already developed tumors, but today it is known that the process of cancer formation begins much earlier, in the apparently “normal” tissue surrounding malignant cells. This tumor-adjacent tissue often shows early genetic and molecular changes that predispose it to invasive cancer.
The study by Foda et al. (2024) specifically set out to analyze these early transformations. The researchers compared gene expression patterns from normal breast tissue with those from “tumor-adjacent” tissue, and then evaluated how these same genes responded to atorvastatin treatment. To do so, they used three publicly available datasets from the Gene Expression Omnibus (GEO) database, which compiles gene expression analyses from thousands of patients.
Using advanced bioinformatic tools, the researchers integrated the data, eliminated statistical noise, and focused on differentially expressed genes (DEGs), those showing significant changes between healthy and at-risk tissue.
The Genetic Footprint of Risk
The analysis revealed 116 altered genes between normal and tumor-adjacent tissues. Many of them were involved in essential biological processes such as inflammation, DNA repair, oxidative stress response, and cell cycle control. These alterations indicate that even before a visible tumor forms, cells in the surrounding breast environment begin to behave abnormally, activating pathways that may lead to malignancy.
Then, when analyzing samples from patients treated with atorvastatin, the researchers identified 105 genes whose activity changed after treatment. By intersecting both datasets, they found something remarkable: 13 genes overlapped. These genes were not only altered in at-risk tissue but returned to normal levels after atorvastatin treatment.
This finding is crucial. It means that atorvastatin does not act only on blood cholesterol but also on the molecular mechanisms that predispose to breast cancer—reversing an “early tumorigenic signature.”
The 13 Genes That Could Make a Difference
These 13 genes are related to key processes such as inflammation, apoptosis (programmed cell death), oxidative stress, immune regulation, and cell cycle control. When these mechanisms fail, damaged or mutated cells can survive, facilitating the onset of cancer.
According to the study, atorvastatin may “reprogram” the expression of these genes, restoring their natural balance. In fact, the protein–protein interaction (PPI) network analysis showed that these genes are highly interconnected, forming a coordinated cellular defense cluster. By normalizing their expression, the drug could strengthen the breast tissue’s ability to resist the earliest steps of cancer transformation.
Figure 1. Originally used as a cholesterol-lowering drug, atorvastatin has been shown to normalize the expression of 13 dysregulated genes involved in inflammation, oxidative stress, DNA repair, and cell death pathways. By restoring these gene expression patterns, atorvastatin may help reestablish a protective cellular environment and counteract early tumor-promoting signals in adjacent breast tissue.
These observations suggest that atorvastatin could act as a comprehensive modulator of the breast microenvironment, reducing inflammatory stimuli and reactivating the body’s natural mechanisms of cellular control.
Reprogramming the Immune System
The study did not limit itself to genetic analysis. It also explored how atorvastatin affects the immune microenvironment of breast tissue. Using a computational technique called deconvolution, the scientists estimated the types and proportions of immune cells present before and after treatment.
The results were remarkable: tumor-adjacent tissues showed an increase in regulatory T cells (Tregs), which usually suppress immune responses and allow cancer cells to escape immune control. However, after atorvastatin treatment, the number of Tregs decreased, while monocytes and activated memory T cells increased—both cell types associated with a more effective response against abnormal cells.
In summary, atorvastatin appears to transform a passive, permissive immune environment into a more active and protective one, enhancing immune surveillance and reducing conditions that favor tumor growth.
Lower Aggressiveness and Better Prognosis
When the researchers compared the expression levels of the 13 genes in large breast cancer databases (such as TCGA-BRCA), they observed that patients with low levels of these genes had more aggressive tumors and a higher mutational burden, including mutations in TP53, one of the most important tumor suppressor genes.
Conversely, patients with high expression levels of these genes showed better prognoses—both in overall survival and disease-free survival. Of the 13 genes, 12 were associated with a reduced risk of death or relapse, reinforcing the idea that maintaining their activity could be key to preventing cancer progression.
Moreover, the authors noted that alterations in these genes are linked to processes such as genetic instability, hypoxia, and uncontrolled cell proliferation—all hallmarks of advanced tumors. This suggests that regulating these genes early could make the difference between healthy tissue and tissue predisposed to cancer.
An Opportunity in Preventive Medicine
The study by Foda et al. (2024) offers a transformative perspective: common drugs such as atorvastatin could have a preventive role in oncology, beyond their traditional use.
This finding fits within a growing medical research trend known as drug repurposing, which seeks to identify new uses for already approved medications. The advantage of this approach is that these compounds have years of clinical experience and well-established safety profiles, accelerating their potential application in new therapeutic contexts.
The results also reinforce the importance of understanding cancer as a progressive process, in which prevention must begin long before the disease appears. If these findings are confirmed in larger clinical trials, atorvastatin could become an accessible tool to reduce breast cancer risk in vulnerable populations, especially in women with family histories or genetic risk factors.
Main reference:
Foda, M. Y., Salem, M. L., AlAkwaa, F. M., & El-Khawaga, O. Y. (2024). Atorvastatin lowers breast cancer risk by reversing an early tumorigenic signature. Scientific reports, 14(1), 17803. https://doi.org/10.1038/s41598-024-67706-2
Other reference:
de la Mare, J. A., Contu, L., Hunter, M. C., Moyo, B., Sterrenberg, J. N., Dhanani, K. C., Mutsvunguma, L. Z., & Edkins, A. L. (2014). Breast cancer: current developments in molecular approaches to diagnosis and treatment. Recent patents on anti-cancer drug discovery, 9(2), 153–175. https://doi.org/10.2174/15748928113086660046
Wu, Q., Li, B., Li, Z., Li, J., Sun, S., & Sun, S. (2019). Cancer-associated adipocytes: key players in breast cancer progression. Journal of hematology & oncology, 12(1), 95. https://doi.org/10.1186/s13045-019-0778-6
Ma L. (2014). Determinants of breast cancer progression. Science translational medicine, 6(243), 243fs25. https://doi.org/10.1126/scitranslmed.3009587
